CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Avastin® (bevacizumab) +1 moredrug
Likely dose
Avastin® (bevacizumab) 0.1 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01072357
NCT01072357Phase 2Completed
CompareCT.gov

Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

Reza Dana, MD·interventional·Posted Feb 22, 2010·Updated Jun 15, 2018

In Brief

A Phase 2 clinical trial evaluating Avastin® (bevacizumab) and 0.9% NaCl & Refresh Liquigel for Corneal Neovascularization and Corneal Graft Failure. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The leading risk factor for corneal transplant rejection is abnormal blood vessel growth of the host bed. Vascular endothelial growth factor (VEGF) is thought to be a mediator of this corneal neovascularization (NV), therefore we would like to test the safety and efficacy of local VEGF blockade in the promotion of graft survival in high risk corneal transplants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCorneal Neovascularization, Corneal Graft Failure
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 22, 2010
Enrollment StartDec 1, 2009
Primary CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 16.4 years ago

Interventions

Avastin® (bevacizumab)drug

One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.

0.9% NaCl & Refresh Liquigeldrug

One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks